US 11,840,568 B2
Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
Shaoxiong Wang, Shanghai (CN); John L. Xu, Shanghai (CN); Jing Zhao, Shanghai (CN); Ming Wang, Shanghai (CN); Juehua Xu, Shanghai (CN); and Fei Song, Shanghai (CN)
Assigned to MAB-VENTURE BIOPHARM CO., LTD., Shanghai (CN)
Appl. No. 17/044,524
Filed by MAB-VENTURE BIOPHARM CO., LTD., Shanghai (CN)
PCT Filed Apr. 1, 2019, PCT No. PCT/CN2019/080847
§ 371(c)(1), (2) Date Oct. 1, 2020,
PCT Pub. No. WO2019/192432, PCT Pub. Date Oct. 10, 2019.
Claims priority of application No. PCT/CN2018/081636 (WO), filed on Apr. 2, 2018.
Prior Publication US 2021/0147536 A1, May 20, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. An isolated anti-LAG-3 antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
(a) a heavy chain variable region CDR1 comprising the sequence SYGIS (SEQ ID NO: 88);
(b) a heavy chain variable region CDR2 comprising the sequence WISAYNGNTNYAQKLQG (SEQ ID NO: 89), and
(c) a heavy chain variable region CDR3 comprising the sequence DGWWELLRPDDAFDI (SEQ ID NO: 90), and
the light chain variable region comprises:
(d) a light chain variable region CDR1 comprising the sequence SGDKLGDKYAY (SEQ ID NO: 91),
(e) a light chain variable region CDR2 comprising the sequence YDSDRPS (SEQ ID NO: 92), and
(f) a light chain variable region CDR3 comprising the sequence QVWDSSSDQW (SEQ ID NO: 93).